EverSource Wealth Advisors LLC Purchases 201 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

EverSource Wealth Advisors LLC increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 79.8% in the 4th quarter, HoldingsChannel reports. The firm owned 453 shares of the company’s stock after acquiring an additional 201 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $187,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Sequoia Financial Advisors LLC lifted its position in IDEXX Laboratories by 6.2% during the fourth quarter. Sequoia Financial Advisors LLC now owns 1,685 shares of the company’s stock worth $697,000 after purchasing an additional 98 shares during the period. PFG Advisors lifted its position in IDEXX Laboratories by 0.7% during the fourth quarter. PFG Advisors now owns 7,465 shares of the company’s stock worth $3,086,000 after purchasing an additional 50 shares during the period. AGF Management Ltd. bought a new stake in IDEXX Laboratories during the fourth quarter worth about $516,000. Inspire Advisors LLC lifted its position in IDEXX Laboratories by 15.2% during the fourth quarter. Inspire Advisors LLC now owns 1,241 shares of the company’s stock worth $513,000 after purchasing an additional 164 shares during the period. Finally, King Luther Capital Management Corp lifted its position in IDEXX Laboratories by 3.7% during the fourth quarter. King Luther Capital Management Corp now owns 4,872 shares of the company’s stock worth $2,014,000 after purchasing an additional 175 shares during the period. Institutional investors own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.18% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $415.30 on Monday. The business’s 50 day simple moving average is $438.03 and its 200 day simple moving average is $446.76. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88. The stock has a market capitalization of $33.78 billion, a PE ratio of 38.92, a PEG ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Wall Street Analyst Weigh In

Several brokerages have commented on IDXX. Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Bank of America boosted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Morgan Stanley lowered their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.